Abstract:Chronic inflammation plays a crucial role in the onset and progression of pathologies like neurodegenerative and cardiovascular diseases, diabetes, and cancer, since tumor development and chronic inflammation are linked, sharing common signaling pathways. At least 20% of breast and colorectal cancers are associated with chronic inflammation triggered by infections, irritants, or autoimmune diseases. Obesity, chronic inflammation, and cancer interconnection underscore the importance of population-based interventions in maintaining healthy body weight, to disrupt this axis. Given that the dietary inflammatory index is correlated with an increased risk of cancer, adopting an anti-inflammatory diet supplemented with nutraceuticals may be useful for cancer prevention. Natural products and their derivatives offer promising antitumor activity with favorable adverse effect profiles; however, the development of natural bioactive drugs is challenging due to their variability and complexity, requiring rigorous research processes. It has been shown that combining anti-inflammatory products, such as non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and statins, with plant-derived products demonstrate clinical utility as accessible adjuvants to traditional therapeutic approaches, with known safety profiles. Pharmacological approaches targeting multiple proteins involved in inflammation and cancer pathogenesis emerge as a particularly promising option. Given the systemic and multifactorial nature of inflammation, comprehensive strategies are essential for long term success in cancer therapy. To gain insights into carcinogenic phenomena and discover diagnostic or clinically relevant biomarkers, is pivotal to understand genetic variability, environmental exposure, dietary habits, and TME composition, to establish therapeutic approaches based on molecular and genetic analysis. Furthermore, the use of endocannabinoid, cannabinoid, and prostamide-type compounds as potential therapeutic targets or biomarkers requires further investigation. This review aims to elucidate the role of specific etiological agents and mediators contributing to persistent inflammatory reactions in tumor development. It explores potential therapeutic strategies for cancer treatment, emphasizing the urgent need for cost-effective approaches to address cancer-associated inflammation.

Relationship Between Inflammation and Cancer and Its Clinical Significance

From Inflammation to Cancer: the Molecular Basis

Reactive Oxygen Species Bridge the Gap between Chronic Inflammation and Tumor Development

Myeloid-derived Suppressor Cells: Connection Between Inflammation and Cancer

Chronic inflammation, cancer development and immunotherapy

Inflammation and tumor progression: signaling pathways and targeted intervention

Prevention and treatment of cancer targeting chronic inflammation: research progress, potential agents, clinical studies and mechanisms

The Role of Tumor Inflammatory Microenvironment in Lung Cancer

Effects of immune cells and cytokines on inflammation and immunosuppression in the tumor microenvironment

Mutation-promoting molecular networks of uncontrolled inflammation

The Interplay Between Inflammation and Stromal Components in Pancreatic Cancer

Targeting the Inflammatory Pathways to Enhance Chemotherapy of Cancer

Association between Inflammation and Function of Cell Adhesion Molecules Influence on Gastrointestinal Cancer Development

The relationship between nonresolving inflammation and oral squamous cell carcinoma

Crosstalk between Environmental Inflammatory Stimuli and Non-Coding RNA in Cancer Occurrence and Development

Interplay Between Inflammatory Tumor Microenvironment and Cancer Stem Cells.

Chronic Inflammation in Skin Malignancies

Identification of inflammatory response-related molecular mechanisms based on the ATM/ATR/p53 pathway in tumor cells

Research Progress on the Relationship Between Inflammation and Colorectal Cancer

Inflammation and cancer: friend or foe?

Inflammation and Cancer: Paradoxical Roles in Tumorigenesis and Implications in Immunotherapies